Home > Maligne hematologie > Lymfoïde ziekten > Plasmaceldyscrasieën > Multipel myeloom > Cartitude 5 / 68284528MMY3004

Printen

Versie:	1.0.0
Revisie:	30-09-2022
Type:	Studie
Status:	Gesloten voor inclusie
Ziektebeeld:	Multipel myeloom
Behandellijn:	1ste lijn
Fase:	Fase 3
Leeftijd:	≥ 18
PI:	Dr. W.W.H. Roeloffzen
TC:	M. de Vries
Titel:	A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Cartitude 5 / 68284528MMY3004

Studieprotocol

Cartitude 5 / 68284528MMY3004 Protocol

ICF

Cartitude 5 / 68284528MMY3004 Proefpersoneninformatie

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Cartitude 5 / 68284528MMY3004

Hematologie Groningen